GMP standards soon for Russian drug firms
The Russian drug market grew 35% in 2005, as the country continued its recovery from the 1998 economic crisis. A report published by the Novosti Russian news agency outlines the changes in the Russian market, as the indus-try prepares itself for the introduction of Good Manu-facturing Practice standards.
Russia's market "over $9 billion"
According to research published by the DSM Group, the total Russian pharmaceutical market in 2005 amounted to $9.01 billion, or 2.0% of the global sector. The figure includes medicines, biologically-active food additives and medical preparations. Only Brazil's market grew faster last year, with Russia's growth being comparable to that of China in percentage terms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze